Poster Abstract Session:
137. Clostridium difficile Infections: Treatment and Prevention
Friday, October 9, 2015: 12:30 PM-2:00 PM
Room: Poster Hall

Learning Objectives:

-

Tracks: Adult ID, Pediatric ID, Epidemiology and Infection Control

Presentations:
957
Cost-effectiveness analysis of vancomycin versus metronidazole for management of initial episodes of Clostridium difficile infection in hospitalized patients
Diana Karkow, PharmD ; Mary Schroeder, PhD ; Dilek Ince, MD ; Erika Ernst, PharmD
Posters
  • IDWeek Cdiff CEA Poster.pdf (204.4 kB)
    • 958
    A Comparison of Clostridium difficile Recurrence Rates with Different Treatment Methods
    Rohini Dave, PharmD ; Sima Madhiwala, PharmD, BCPS ; Patrick Waters, PharmD, AAHIVP ; Lisa Young, Pharm.D., BCPS AQ-ID
    959
    Relapsing Clostridium difficile Associated Disease Followed by a Registry and Fecal Microbiota Transplant Attitudes Questionnaire
    Alfred E. Bacon III, MD ; Danielle Mosby, MPH ; Claudine Jurkovitz, MD ; Bailey Ingraham Lopresto, MS ; Marci Drees, MD, MS ; Anand Panwalker, MD, FIDSA ; Patty Mcgraw, RN, MS
    960
    Nap1 positivity predicts metronidazole failure in a cohort of patients with Non-severe Clostridium difficile-associated diarrhea
    Lemuel Non, MD ; Anastasios Dimou, MD ; Juliana Da Silva, MD ; Gentry King, MD ; Sherilyn Tuazon, MD ; Jerry Zuckerman, MD, FSHEA
    Posters
  • Nap1 poster for IDSA.pdf (439.7 kB)
    • 961
    Treatments and outcomes for Clostridium difficile infection (CDI) in patients with HIV infection
    Siyun Liao, PharmD, PhD ; Melissa Badowski, PharmD ; Robert Glowacki, PharmD ; Patricia Herrera, MD
    Posters
  • ID 2015 poster C diff HIV.pdf (216.8 kB)
    • 962
    Prospective Assessment of Donor Eligibility for Fecal Microbiota Transplantation at a Public Stool Bank: Results From the Evaluation of 1,387 Candidate Donors
    Nancy Dubois, MSN, MBA ; Kelly Ling, BA ; Majdi Osman, MD, MPH ; Larua Burns, BS ; Gina Mendolia, BA ; Dan Blackler, BS ; James Burgess, BA ; Carolyn Edelstein, MPA ; Andrew Noh, BBA ; Elaine Vo, PhD ; Eric Alm, PhD ; Mark Smith, PhD ; Zain Kassam, MD, MPH
    964
    Development of A Fecal Microbiota Transplant (FMT) Program for Relapsing Clostridium difficile Disease(CDAD)
    Alfred E. Bacon III, MD ; Fedele Depalma, MD ; Marcianna Filippone, MD ; Christine Herdman, MD ; Scott Myerson, MD ; Marci Drees, MD, MS ; Anand Panwalker, MD, FIDSA ; Chad Duffalo, MD ; Richard Bowling, CPA MBA ; Patty Mcgraw, RN, MS
    965
    Fecal Microbiota Transplant for Recurrent C. difficile Infection: The Patient Experience
    Amy Pakyz, PharmD, MS, PhD ; Leticia Moczygemba, PharmD, PhD ; Lynn Vanderwielen, MPH, PhD ; Michael Edmond, MD, MPH, MPA, FIDSA, FSHEA
    966
    Implementation and outcomes of Fecal Microbiota Transplantation in a Four Hospital System
    Adrienne Kercsak, PharmD ; Eva Sullivan, PharmD ; Harminder Sikand, PharmD, FCSHP, FASHP
    Posters
  • Fecal Transplant poster IDSA 10.7.15.pdf (708.0 kB)
    • 967
    Fecal Microbiota Transplantation – A Safe and Effective Treatment for Clostridium difficile Infection in Stem Cell Transplantation
    Mayur Ramesh, MD ; Abinav Deol, MD ; Rachna Jayaprakash, MD ; Odaliz Abreu-Lanfranco, MD ; George Alangaden, MD, FIDSA ; Joseph Uberti, MD ; Sanjay Revankar, MD ; Pranatharthi Chandrasekar, MD, FIDSA
    Posters
  • FMT in BMT poster.pdf (325.8 kB)
    • 968
    Attitudes Toward Fecal Microbiota Transplantation Among Patients with C. difficile
    Marci Drees, MD, MS ; Patty Mcgraw, RN, MS ; Boniface Fogwe, BS ; Alfred E. Bacon III, MD ; Chad Duffalo, MD, MPH
    Posters
  • Drees_FMT patient survey_IDWeek2015poster_FINAL.pdf (887.6 kB)
    • 969
    Evaluating Veterans Affairs (VA) Acute Care Facilities for Clostridium difficile Infections (CDIs) Using a Targeted Assessment for Prevention (TAP) Strategy
    Martin Evans, MD, FIDSA, FSHEA ; Stephen Kralovic, MD, MPH, FSHEA ; Loretta Simbartl, MS ; Gary Roselle, MD, FIDSA
    970
    City-wide Collaboration to Reduce C. difficile Infections
    Christina Felsen, MPH ; Gail Quinlan, RN, MSN ; Nayef El-Daher, MD, PhD ; Donna Farnsworth, R.N. ; Paul Graman, MD, FIDSA, FSHEA ; Linda Greene, RN, MPS, CIC ; Maryrose Laguio, MD ; Mark Shelly, MD, FSHEA ; Ann Marie Pettis, RN, BSN, CIC ; Wan Tang, PhD ; Xin Tu, PhD ; Susan Messing, MS, MA ; Elizabeth Dodds Ashley, PharmD, MHS ; Ghinwa Dumyati, MD, FSHEA
    Posters
  • Poster 970.pdf (359.1 kB)
    • 971
    Hospital-wide Evaluation of Probiotic Administration as Primary Prevention of Clostridium difficile infection (CDI) in a Tertiary Care Hospital
    William Trick, MD ; Stephen Sokalski, DO ; Joseph Levato, Pharm D ; Rolla Sweis, Pharm D ; Surej Veleeparambil, MBBS ; Stuart Johnson, MD, FIDSA ; Robert a. Weinstein, MD, FIDSA, FSHEA
    Posters
  • IDWeek_2015_probiotics_version 2.1.pdf (361.4 kB)
    • 972
    Provider Compliance with Clostridium Difficile Precautions in an Academic Emergency Department
    Michael Pulia, MD ; John Harringa, BS ; Brian Sharp, MD ; Samuel Zidovetzki, MD ; Azita Hamedani, MD, MPH, MBA ; Nasia Safdar, MD, PhD, FSHEA
    973
    Breaking Down the Bundle: Using Quality Improvement Science to Control  C difficile Transmission in a Community Hospital
    Barbara Lambl, MD MPH ; Maureen Duram, RN, CPHQ ; Monique Freeley, RPh ; Nathan Kaufman, MD ; William O'neill, BA ; Janice Kurowski, RN ; Marc Rubin, MD ; Paul Seeley, BA ; Frederick Buckley, MD ; Mary Jo Gagnon, BS, MBA ; Wendy Krauss, RN ; Lana Danish, RN ; Jonelle Oconnor, RN
    Posters
  • IDSA 2015 Poster.jpg (140.4 kB)

    • CME Credits:

    ACPE Credits:

    ACPE Number:


    See more of: Poster Abstract Session
    << Previous Session | Next Session >>

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.